Clinical Trial Update: Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. [Phase 3]

View source ↗

Summary

Phase 3 study of rivaroxaban (BAY 59-7939) for prevention of venous thromboembolism in adults undergoing elective total knee replacement has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Prevention, Venous Thromboembolism | Phase 3 | Status: COMPLETED